These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 10901964)

  • 1. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.
    Allen BJ
    Australas Radiol; 1999 Nov; 43(4):480-6. PubMed ID: 10901964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancements in cancer therapy with alpha-emitters: a review.
    Imam SK
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149.
    Allen BJ; Blagojevic N
    Nucl Med Commun; 1996 Jan; 17(1):40-7. PubMed ID: 8692472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
    Abbas Rizvi SM; Sarkar S; Goozee G; Allen BJ
    Melanoma Res; 2000 Jun; 10(3):281-9. PubMed ID: 10890383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
    Zalutsky MR; Bigner DD
    Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
    Kozempel J; Mokhodoeva O; Vlk M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy with α-particle-emitting radionuclides.
    Seidl C
    Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted alpha therapy for cancer.
    Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Zhang D; Song E; Qu CF; Kearsley J; Graham P; Thompson J
    Phys Med Biol; 2004 Aug; 49(16):3703-12. PubMed ID: 15446799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
    Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
    J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
    Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R
    Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
    Allen BJ; Rizvi S; Li Y; Tian Z; Ranson M
    Crit Rev Oncol Hematol; 2001; 39(1-2):139-46. PubMed ID: 11418311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer radioimmunotherapy with alpha-emitting nuclides.
    Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted alpha-particle immunotherapy for acute myeloid leukemia.
    Jurcic JG; Rosenblat TL
    Am Soc Clin Oncol Educ Book; 2014; ():e126-31. PubMed ID: 24857092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Appendix of Radionuclides Used in Targeted Alpha Therapy.
    Ferrier MG; Radchenko V
    J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S58-S65. PubMed ID: 31427258
    [No Abstract]   [Full Text] [Related]  

  • 19. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation.
    Wulbrand C; Seidl C; Gaertner FC; Bruchertseifer F; Morgenstern A; Essler M; Senekowitsch-Schmidtke R
    PLoS One; 2013; 8(5):e64730. PubMed ID: 23724085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
    Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
    J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.